Further complexities in diagnosing acquired thrombocytopenia: unexpected parallels between antibody-mediated delayed thrombocytopenia with abciximab and heparin induced thrombocytopenia

Thromb Haemost 2004; 92(04): 674-675
DOI: 10.1160/TH04-07-0446

Editorial Focus

Schattauer GmbH

Catherine P. M. Hayward

¹Departments of Pathology and Molecular Medicine, and Medicine, McMaster University, Hamilton, Ontario, Canada

References
1 Aster RH. Drug-Induced Thrombocytopenia. In: Platelets. Edited by Michelson AD. Academic Press; New York: 2002: 593-606.
2 Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost 2001; 86: 427-43.
3 Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121: 535-55.
4 Fareed J, Hoppensteadt DA, Bick RL. Management of thrombotic and cardiovascular disorders in the new millenium. Clin Appl Thromb Hemost 2003; 09: 101-8.
5 Ibbotson T, McGavin JK, Goa KL. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs 2003; 63: 1121-63.
6 Abrams CS, Cines DB. Thrombocytopenia after treatment with platelet glycoprotein IIb/IIIa inhibitors. Curr Hematol Rep 2004; 03: 143-7.
7 Nurden P, Clofent-Sanchez G, Jais C. et al. Delayed immunologic thrombocytopenia induced by abciximab. Thromb Haemost 2004; 92: 820-8.
8 Curtis BR, Divgi A, Garrity TM. et al. Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug. J Thromb Haemost 2004; 02: 985-92.